MedTrace Logo

Comparing Hydrocortisone and Prednisolone for Community Acquired Pneumonia (CAP)

NCT06892197 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1600

Last updated 2026-03-18

No results posted yet for this study

Summary

The goal of this cluster randomized controlled trial is to determine the optimal treatment for community aquired pneumonia (CAP). The study compares the effects and side effects of hydrocortisone and prednisolone in patients above 18 years old diagnosed with severe CAP. The main question is whether there is a difference in all cause mortality within thirty days.

Participants will be randomized to receive treatment with either hydrocortisone or prednisolone.

Conditions

  • Community Acquired Pneumonia (CAP)

Interventions

DRUG

Methylprednisolone (drug)

ATC code: H02AB06. Can be changed to Prednisolone 50 mg orally.

DRUG

hydrocortisone

ATC-code: H02AB09. Can be changed to 50 mg x 4 daily orally if appropriate.

Sponsors & Collaborators

  • Copenhagen Respiratory Research

    lead NETWORK

Principal Investigators

  • Jens-Ulrik Stæhr Jensen, MD, PHD · COP:RESP

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-10
Primary Completion
2030-08-01
Completion
2030-11-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06892197 on ClinicalTrials.gov